AFMID (arylformamidase) catalyzes the hydrolysis of N-formyl-L-kynurenine to L-kynurenine, representing a critical step in the kynurenine pathway of tryptophan degradation 1. This enzymatic activity is conserved across invertebrate and vertebrate organisms, with AFMID-like sequences identified in model organisms including pond snails 2. The kynurenine pathway ultimately leads to nicotinic acid and NAD(H) synthesis, essential for cellular energy metabolism and detoxification 3. In cancer biology, AFMID function is dysregulated through multiple mechanisms. Alternative splicing of AFMID occurs early during hepatocellular carcinoma (HCC) development and is associated with TP53 and ARID1A driver mutations; overexpression of full-length AFMID increases cellular NAD+ levels and reduces DNA damage response 3. In colon cancer, MYC-driven metabolic reprogramming upregulates AFMID expression to promote tryptophan-to-kynurenine conversion, supporting aryl hydrocarbon receptor (AHR) activation and cancer cell proliferation 1. Conversely, AFMID is significantly downregulated in clear cell renal cell carcinoma, and its overexpression inhibits cell proliferation and alters lipid metabolism pathways 4. AFMID expression is also altered in non-malignant diseases. Aberrant DNA methylation of AFMID in proximal tubules correlates with kidney dysfunction in diabetic nephropathy 5, while dysregulated AFMID expression occurs in uterine fibroids alongside other tryptophan pathway enzymes 6. These findings establish AFMID as a context-dependent metabolic regulator with therapeutic relevance across multiple disease states.